Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Pyrilutamide
2. Schembl1444126
3. Ex-a5504
4. Hy-145451
5. Cs-0374724
6. 1272719-00-2
7. 4-[3-[4-cyano-2-fluoro-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-n-methylbenzamide
| Molecular Weight | 482.4 g/mol |
|---|---|
| Molecular Formula | C21H15F5N4O2S |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 3 |
| Exact Mass | 482.08358772 g/mol |
| Monoisotopic Mass | 482.08358772 g/mol |
| Topological Polar Surface Area | 109 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 873 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
KX-826 (pyrilutamide) is a monoclonal antibody drug candidate with potential AR antagonistic action, is being developed as a potential topical drug for the treatment of androgenic alopecia and acne vulgaris.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Brand Name: KX-826
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KX-826 (pyrilutamide) is a monoclonal antibody drug candidate with potential AR antagonistic action, is being developed as a potential topical drug for the treatment of androgenic alopecia and acne vulgaris.
Brand Name : KX-826
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 11, 2023
Details:
KX-826 (pyrilutamide) is a monoclonal antibody drug candidate with potential AR antagonistic action, is being developed as a potential topical drug for the treatment of androgenic alopecia and acne vulgaris.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Brand Name: KX-826
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KX-826 (pyrilutamide) is a monoclonal antibody drug candidate with potential AR antagonistic action, is being developed as a potential topical drug for the treatment of androgenic alopecia and acne vulgaris.
Brand Name : KX-826
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 28, 2023
Details:
KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. KX-826 has demonstrated clinically meaningful and statistically significant improvement in hair growth.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Brand Name: KX-826
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. KX-826 has demonstrated clinically meaningful and statistically significant improvement in hair growth.
Brand Name : KX-826
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 01, 2022
Details:
KX-826 (pyrilutamide) is an AR antagonist and a potential first-in-class topical drug for treatment of androgenetic alopecia and acne vulgaris continues to demonstrate good efficacy and safety in phase II clinical trial to benefit more people suffering from acne vulgaris.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Brand Name: KX-826
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2022
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KX-826 (pyrilutamide) is an AR antagonist and a potential first-in-class topical drug for treatment of androgenetic alopecia and acne vulgaris continues to demonstrate good efficacy and safety in phase II clinical trial to benefit more people suffering f...
Brand Name : KX-826
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 16, 2022
Details:
KX-826 (pruxelutamide) effectively reduced hospitalization/mortality; in particular, for subjects who completed the medication for more than 7 days and middle-and-high-age COVID-19 patients with high risk factors, the protection rate was 100%.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Brand Name: KX-826
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: IQVIA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : IQVIA
Deal Size : Not Applicable
Deal Type : Not Applicable
Kintor Announces 2022 Interim Results and Recent Business Update
Details : KX-826 (pruxelutamide) effectively reduced hospitalization/mortality; in particular, for subjects who completed the medication for more than 7 days and middle-and-high-age COVID-19 patients with high risk factors, the protection rate was 100%.
Brand Name : KX-826
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 29, 2022
Details:
Kintor Pharma announced that the primary endpoint of the phase II clinical trial of KX-826 (pyrilutamide) on adult male patients was met, with results demonstrating a positive safety profile and good efficacy.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Brand Name: KX-826
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Kintor Pharma announced that the primary endpoint of the phase II clinical trial of KX-826 (pyrilutamide) on adult male patients was met, with results demonstrating a positive safety profile and good efficacy.
Brand Name : KX-826
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2022
Details:
KX-826 is an androgen receptor antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. The primary endpoint of the phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficacy and safety profile.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Brand Name: KX-826
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2022
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KX-826 is an androgen receptor antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. The primary endpoint of the phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficac...
Brand Name : KX-826
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 06, 2022
Details:
KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. KX-826 has showed good efficacy and safety profile in the phase II clinical trial in China for the treatment of AGA male patients.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Brand Name: KX-826
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. KX-826 has showed good efficacy and safety profile in the phase II clinical trial in China for the treatment of AGA mal...
Brand Name : KX-826
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2022
Details:
KX-826 (pyrilutamide) is first androgen receptor antagonist which has entered phase III clinical trial for male androgenetic alopecia treatment in China and global. Primary endpoint of KX-826 on male AGA patients met and demonstrated outstanding efficacy and safety profile.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Brand Name: KX-826
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2021
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kintor Pharma Receives IND Clearance by NMPA for KX-826’s Pivotal Study to Treat Male Alopecia P...
Details : KX-826 (pyrilutamide) is first androgen receptor antagonist which has entered phase III clinical trial for male androgenetic alopecia treatment in China and global. Primary endpoint of KX-826 on male AGA patients met and demonstrated outstanding efficacy...
Brand Name : KX-826
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 24, 2021
Details:
The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Pyrilutamide in patients with mild to moderate acne vulgaris.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Brand Name: KX-826
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2021
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Pyrilutamide in patients with mild to moderate acne vulgaris.
Brand Name : KX-826
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Pyrilutamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pyrilutamide, including repackagers and relabelers. The FDA regulates Pyrilutamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pyrilutamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Pyrilutamide supplier is an individual or a company that provides Pyrilutamide active pharmaceutical ingredient (API) or Pyrilutamide finished formulations upon request. The Pyrilutamide suppliers may include Pyrilutamide API manufacturers, exporters, distributors and traders.
Pyrilutamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pyrilutamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pyrilutamide GMP manufacturer or Pyrilutamide GMP API supplier for your needs.
A Pyrilutamide CoA (Certificate of Analysis) is a formal document that attests to Pyrilutamide's compliance with Pyrilutamide specifications and serves as a tool for batch-level quality control.
Pyrilutamide CoA mostly includes findings from lab analyses of a specific batch. For each Pyrilutamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pyrilutamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Pyrilutamide EP), Pyrilutamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pyrilutamide USP).
LOOKING FOR A SUPPLIER?
